Roche says Alzheimer’s antibody gets U.S. breakthrough designation

Stock Markets21 minutes ago (Oct 08, 2021 12:31PM ET)

(C) Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

ZURICH (Reuters) -Roche said on Friday its gantenerumab antibody had received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease.

Like many other drug prospects to treat this debilitating disease, gantenerumab is designed to neutralise beta-amyloid plaques seen as a driver behind brain cell death.

The Swiss pharmaceutical giant said the U.S. breakthrough designation was based on data showing that gantenerumab had significantly reduced brain amyloid plaque in ongoing trials.

Levi Garraway, chief medical officer and head of global product development at Roche, said the designation “reinforces our confidence in gantenerumab, which would be the first subcutaneous medicine for the treatment of Alzheimer’s disease with the potential for at-home administration.”

Analysts had said there could be an expedited filing for U.S. regulatory approval of gantenerumab, which could be a blockbuster if shown to work.

Pursuit of an Alzheimer’s remedy, which would inevitably reap drugmakers billions of dollars, has been marked by more than 100 failures, although researchers still hope to tame a condition that affects nearly 6 million Americans, more than 40 million people worldwide, and which is growing more prevalent.

Roche will complete a Phase III trial of the medicine in the second half of next year. In July, Chief Executive Severin Schwan said it was urgent to find a way to treat this unmet medical need and bring treatment to patients as soon as possible.

Roche says Alzheimer’s therapy gets U.S. breakthrough designation

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Join the exclusive subscription today and get premium articles for free

Up Next